The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma

William J. Anderson, Philip M. Short, Peter A. Williamson, Arvind Manoharan, Brian J. Lipworth (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    13 Citations (Scopus)

    Abstract

    The murine asthma model shows that switching off airway ß2 receptors with an inverse agonist may confer anti-inflammatory effects as well as corticosteroid-sparing activity. We have assessed for any corticosteroid-sparing effects of propranolol, an inverse agonist, added to low-dose inhaled corticosteroid (ICS) compared with higher dose ICS. A randomized double-blind placebo-controlled cross-over trial in mild-to-moderate persistent asthmatic patients was performed. After a run-in (2 weeks) on hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) at 100 µg/day (HFA-BDP100), patients received randomized treatments (4 weeks) with propranolol at 80 mg/day plus HFA-BDP at 100 µg/day compared with placebo plus HFA-BDP at 400 µg/day (HFA-BDP400). Propranolol was up-titrated to 80 mg/day over the initial 2 weeks. Tiotropium was co-administered until 5 days before each histamine challenge (the primary outcome). Sixteen patients completed the study [mean age, 38 years; forced expiratory volume in 1 s (FEV1), 86.4%; histamine provocative concentration causing a 20% fall in FEV1 (PC20), 1.39 mg/ml; ICS dose, 406 µg/day]. Histamine PC20 was unchanged by adding propranolol to HFA-BDP100 compared with baseline (HFA-BDP100) {0.17 doubling dilution (dd) difference [95% confidence interval (CI): -0.58 to 0.92]}, but there was a significant improvement with HFA-BDP400 compared with both baseline [1.05 dd (95% CI: 0.43-1.66); P=0.02], and propranolol+HFA-BDP100 [0.88 dd (95% CI: 0.45-1.30); P=0.006]. Significant improvements were also observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils, serum eosinophilic cationic protein and asthma quality-of-life questionnaire symptoms compared with propranolol+HFA-BDP100. Salbutamol recovery post-challenge was partially blunted by propranolol (median prolongation 5 min; P=0.002). Domiciliary evening FEV1 also fell with propranolol+HFA-BDP100 [mean reduction from baseline 0.22 litres (95% CI: 0.10-0.34); P=0.012], whereas Asthma Control Questionnaire remained unchanged. In conclusion, the inverse agonist propranolol produced no improvements when given with low-dose ICS, whereas further significant improvements in airway hyper-responsiveness and inflammation were demonstrated with higher dose ICS. Thus, propranolol does not confer corticosteroid-sparing activity in persistent asthma.
    Original languageEnglish
    Pages (from-to)635-643
    Number of pages9
    JournalClinical Science
    Volume127
    Issue number11
    DOIs
    Publication statusPublished - Dec 2014

    Keywords

    • Adult
    • Asthma
    • Beclomethasone
    • Bronchial Provocation Tests
    • Creatinine
    • DNA-Binding Proteins
    • Double-Blind Method
    • Eosinophilia
    • Female
    • Humans
    • Hydrocarbons, Fluorinated
    • Hydrocortisone
    • Male
    • Nuclear Proteins
    • Potassium
    • Propranolol

    Fingerprint Dive into the research topics of 'The inverse agonist propranolol confers no corticosteroid-sparing activity in mild-to-moderate persistent asthma'. Together they form a unique fingerprint.

  • Profiles

    No photo of Brian Lipworth

    Lipworth, Brian

    Person: Academic

    Cite this